Regenxbio (RGNX) Return on Sales [ROS] (2014 - 2026)
Regenxbio's Return on Sales [ROS] came in at 27.09% for Q2 2026, up 323.35 percentage points from -296.26% a year earlier.
Powered by 
Analysis
Regenxbio (RGNX) Return on Sales [ROS] (2014 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Regenxbio reported Return on Sales [ROS] of -76.04%, up 29.62 percentage points year-over-year; for FY2025, it came in at -94.58%, up 185.46 percentage points from FY2024.
- Return on Sales [ROS] carries a five-year change of -17.44 percentage points (FY2020 to FY2025).
- Going back by year, Return on Sales [ROS] was -280.03% in FY2024 (+17.09 pp), -297.12% in FY2023 (-63.92 pp), -233.20% in FY2022 (-267.22 pp) and 34.01% in FY2021 (+111.15 pp).
- The Q2 2026 figure represents the highest quarterly Return on Sales [ROS] since Q4 2021.
- Year-over-year, Return on Sales [ROS] increased in five of the last seven quarters, with an average year-over-year change of +120.99 percentage points.
- The fastest year-over-year change in Return on Sales [ROS] over five years came in Q1 2025 (a gain of 422.43 percentage points), and the weakest in Q4 2022 (a drop of 262.97 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Regenxbio | 402.44 Mn | -530.65 Mn | - | 27.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.09% |
| Dec 31, 2025 | -189.99% |
| Sep 30, 2025 | -176.27% |
| Jun 30, 2025 | -296.26% |
| Mar 31, 2025 | 13.62% |
| Dec 31, 2024 | -242.14% |
| Sep 30, 2024 | -256.55% |
| Jun 30, 2024 | -251.34% |
| Mar 31, 2024 | -408.80% |
| Dec 31, 2023 | -287.68% |
| Sep 30, 2023 | -224.67% |
| Jun 30, 2023 | -365.96% |
| Mar 31, 2023 | -345.68% |
| Dec 31, 2022 | -184.31% |
| Sep 30, 2022 | -267.97% |
| Jun 30, 2022 | -191.53% |
| Mar 31, 2022 | -321.93% |
| Dec 31, 2021 | 78.66% |
| Sep 30, 2021 | -186.36% |
| Jun 30, 2021 | -237.01% |
API Access
Regenxbio Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=RGNX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "RGNX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=RGNX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();